Phase 3 Recruiting NIH
This phase III trial compares early treatment with venetoclax and obinutuzumab versus delayed treatment with venetoclax and obinutuzumab in patients with newly diagnosed high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma.…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04269902
Sites in Indiana: - UChicago Medicine Northwest Indiana — Crown Point, Indiana
- Indiana University/Melvin and Bren Simon Cancer Center — Indianapolis, Indiana
- Reid Health — Richmond, Indiana
Phase 3 Recruiting Academic/Other
This phase III trial tests whether continuous or intermittent zanubrutinib after achieving a complete remission (CR) with rituximab works in older adult patients with mantle cell lymphoma (MCL) who have not received treatment in the past (…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05976763
Sites in Indiana: - Northwest Cancer Center - Crown Point — Crown Point, Indiana
- Northwest Oncology LLC — Dyer, Indiana
- Northwest Cancer Center - Hobart — Hobart, Indiana
- Saint Mary Medical Center — Hobart, Indiana
- Saint Catherine Hospital — Indianapolis, Indiana
Phase 3 Recruiting Network
This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy and immunotherapy (chemo-immunotherapy) for patients with High-Risk B-cell Acute Lymphoblastic Leukemia (B-ALL) improves outcomes. Inotuzumab o…
Sponsor: Children's Oncology Group
NCT ID: NCT03959085
Sites in Indiana: - Riley Hospital for Children — Indianapolis, Indiana
- Ascension Saint Vincent Indianapolis Hospital — Indianapolis, Indiana
Phase 3 Recruiting Industry
Follicular lymphoma (FL) is the second most common B-cell cancer and the most common type of cancer of lymphocytes. Unfortunately, this disease is incurable with conventional treatment and the disease recurs in almost all patients. This st…
Sponsor: Genmab
NCT ID: NCT06191744
Sites in Indiana: - Fort Wayne Medical Oncology and Hematology- South Office /ID# 259583 — Fort Wayne, Indiana
Phase 3 Recruiting Industry
This is a global, randomised, Phase III, multicentre, open-label study evaluating the efficacy, safety and the degree of added benefit of the Surovatamig (AZD0486) plus rituximab combination compared to Investigator's choice of 3 standard …
Sponsor: AstraZeneca
NCT ID: NCT06549595
Sites in Indiana: - Research Site — Fort Wayne, Indiana
Phase 3 Recruiting Industry
The purpose of this study is to evaluate if zilovertamab vedotin with standard treatment can help people live longer without the cancer growing or spreading than people who receive standard treatment alone.
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06717347
Sites in Indiana: - Fort Wayne Medical Oncology and Hematology ( Site 0149) — Fort Wayne, Indiana
Phase 3 Recruiting Industry
The purpose of this study is to collect long-term safety and efficacy data for participants treated with ibrutinib and to provide ongoing access to ibrutinib for participants who are currently enrolled in ibrutinib studies that have been c…
Sponsor: Janssen Research & Development, LLC
NCT ID: NCT01804686
Sites in Indiana: - Indiana University — Goshen, Indiana
Phase 3 Recruiting Industry
This study is researching an experimental drug called odronextamab, referred to as study drug, when used in combination with chemotherapy. The study is focused on patients with Diffuse Large B-cell Lymphoma (DLBCL) that have not been treat…
Sponsor: Regeneron Pharmaceuticals
NCT ID: NCT06091865
Sites in Indiana: - Indiana University Melvin and Bren Simon Comprehensive Cancer Center — Indianapolis, Indiana
- St Vincent Ascension at Peyton Manning Childrens Hospital — Indianapolis, Indiana
- Investigative Clinical Research of Indiana — Noblesville, Indiana
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the efficacy of glofitamab monotherapy compared with an investigator's choice of either rituximab plus bendamustine (BR), or lenalidomide with rituximab (R-Len) in patients with relapsed or refracto…
Sponsor: Hoffmann-La Roche
NCT ID: NCT06084936
Sites in Indiana: - Indiana University — Indianapolis, Indiana
Phase 2 Recruiting NIH
This phase II trial studies the effect of nivolumab in combination with blinatumomab compared to blinatumomab alone in treating patients with B-cell acute lymphoblastic leukemia (B-ALL) that has come back (relapsed). Down syndrome patients…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04546399
Sites in Indiana: - Riley Hospital for Children — Indianapolis, Indiana
Phase 2 Recruiting NIH
This phase II trial tests the addition of venetoclax and/or blinatumomab to usual chemotherapy for treating infants with newly diagnosed acute lymphoblastic leukemia (ALL) with a KMT2A gene rearrangement (KMT2A-rearranged \[R\]) or without…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06317662
Sites in Indiana: - Riley Hospital for Children — Indianapolis, Indiana
Phase 2 Recruiting Network
This phase 2 trial studies the side effects and best dose of tazemetostat and zanubrutinib in combination with tafasitamab and lenalidomide, and to see how well these combinations work in treating patients with large B-cell lymphoma that r…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT05890352
Sites in Indiana: - Northwest Cancer Center - Main Campus — Crown Point, Indiana
- Northwest Oncology LLC — Dyer, Indiana
- Northwest Cancer Center - Hobart — Hobart, Indiana
- Saint Mary Medical Center — Hobart, Indiana
- Saint Catherine Hospital — Indianapolis, Indiana
Phase 2 Recruiting Industry
This is a randomized, open-label study in adult patients who have completed standard first line therapy for large B-cell lymphoma (LBCL) and achieved a complete response or partial response suitable for observation, but who have minimal re…
Sponsor: Allogene Therapeutics
NCT ID: NCT06500273
Sites in Indiana: - IU Simon Comprehensive Cancer Center — Indianapolis, Indiana
- Indiana Blood and Marrow Transplantation — Indianapolis, Indiana
Phase 2 Recruiting Academic/Other
This study will evaluate the use of non- TBI (total body irradiation) conditioning for B-ALL patients with low risk of relapse as defined by absence of NGS-MRD (next generation sequencing minimal residual disease) before receiving a hemato…
Sponsor: Pediatric Transplantation & Cellular Therapy Consortium
NCT ID: NCT03509961
Sites in Indiana: - Riley Hospital for Children - Indiana University — Indianapolis, Indiana
Phase 1, Phase 2 Recruiting Network
This phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come back (recurrent) or does not respond to treatment (refractory). Tegavivint interf…
Sponsor: Children's Oncology Group
NCT ID: NCT04851119
Sites in Indiana: - Riley Hospital for Children — Indianapolis, Indiana
Phase 1, Phase 2 Recruiting Industry
A Phase 1/2a study to assess the safety, tolerability, PK and biological activity of CCS1477 (inobrodib) in patients with Non-Hodgkin Lymphoma, Multiple Myeloma, Acute Myeloid Leukaemia or High Risk Myelodysplastic syndrome.
Sponsor: CellCentric Ltd.
NCT ID: NCT04068597
Sites in Indiana: - Community Health Network — Indianapolis, Indiana
Phase 2 Recruiting Academic/Other
Subjects with relapsed large cell lymphoma will receive 3 cycles of combination therapy consisting of GDP and epcoritamab. Each cycle will last 21 days. GDP consists of gemcitabine 1000 mg/m2 IV on Days 1 and 8, cisplatin 75 mg/m2 IV on Da…
Sponsor: Dipenkumar Modi
NCT ID: NCT05852717
Sites in Indiana: - Indiana University Melvin and Bren Simon Comprehensive Cancer Center — Indianapolis, Indiana
Phase 1 Recruiting Academic/Other
A Phase I trial to determine the safety of targeted immunotherapy with daratumumab (DARA) IV after total body irradiation (TBI)-based myeloablative conditioning and allogeneic hematopoietic cell transplantation (HCT) for children, adolesce…
Sponsor: New York Medical College
NCT ID: NCT04972942
Sites in Indiana: - Riley Children's Hospital — Indianapolis, Indiana
Phase 1 Recruiting Industry
This is an open-label, multi-center Phase 1b clinical study of oral AS-1763 (docirbrutinib) in patients with CLL/SLL or B-cell NHL who have failed or are intolerant to ≥2 lines of systemic therapy.
Sponsor: Carna Biosciences, Inc.
NCT ID: NCT05602363
Sites in Indiana: - American Oncology Partners — Fort Wayne, Indiana
Recruiting Academic/Other
This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05334069
Sites in Indiana: - Reid Health — Richmond, Indiana
Recruiting Academic/Other
This is a multi-site clinical study enrolling 2000 newly diagnosed patients with breast, colorectal, melanoma, non-Hodgkin lymphoma, or non-small cell lung cancer, who are planning to receive one or more systemic cancer directed therapies …
Sponsor: Wake Forest University Health Sciences
NCT ID: NCT06418204
Sites in Indiana: - Woodland Cancer Care Center — Michigan City, Indiana
- Reid Health — Richmond, Indiana
Recruiting Network
This study is an access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) in pediatric and adult patients with hematologic malignancies and other indications.
Sponsor: Center for International Blood and Marrow Transplant Research
NCT ID: NCT01351545
Sites in Indiana: - Indiana Blood & Marrow Transplantation — Beech Grove, Indiana
- Indiana University/Riley Hospital for Children — Indianapolis, Indiana
Recruiting NIH
Background: -Patients who are being evaluated and/or treated at the NIH Clinical Center and adult patients at participating sites will be entered onto this tissue procurement protocol for collection of tissue specimens. Objectives: * To ob…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT00900198
Sites in Indiana: - Indiana University - Purdue — Indianapolis, Indiana